Scott Rocklage and Expansion Therapeutics are Search to Combat RNA Related Disorders
Expansion Therapeutics has recently raised 55.3 million dollars for the purpose of discovering a cure or new therapeutic techniques for myotonic dystrophy type 1 (DM1.)
The disease is caused when RNA levels in the body reach toxic levels and begin to damaging the body from the inside out. Expansion Therapeutics, along with Sanofi Ventures, Novartis Venture Fund, and Kleiner Perkins, in a best case scenario will discover a way to reduce levels of RNA in patients and cease the destruction to bones, organs and tissue. Read more: Scott Rocklage | Bloomberg and Scott Rocklage | Crunchbase
The disease is passed on genetically, so in rare cases entire families could be affected by DM1. A cure for the disease could not only save the lives of individuals but entire families could benefit from a cure.
All research is conducted at a laboratory owned by Matthew D. Disney. Dr. Disney believes that RNA disorders can be treated with small molecule medications. Dr. Disney says that his research will continue until progress is made towards combating diseases related to increased levels of RNA.
ABOUT SCOTT ROCKLAGE
Scott Rocklage received his bachelors degree in Chemistry from the University of California, Berkeley and his PhD in Chemistry at the Massachusetts Institute of Technology. With 30 years of experience in healthcare management, he is currently a Managing Partner of 5AM Ventures.
Rocklage is also Executive Director at Expansion Therapeutics. As a chemist is has invented or co-invented over 30 United States patents and has been published over 100 times. In 2005, Rocklage was awarded the Nobel Peace Prize in Chemistry.
Learn more about Scott Rocklage: https://www.linkedin.com/in/scott-rocklage-66aa7a12a and https://ideamensch.com/scott-rocklage/